RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines
Abstract
Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we describe the production of stabilized mRNA with enhanced immunogenicity, generated using conventional nucleotides only, by introducing changes to the mRNA sequence and by complexation with the nucleotide-binding peptide protamine (RNActive® technology). Methods described here include the synthesis, purification, and protamine complexation of mRNA vaccines as well as a comprehensive panel of in vitro and in vivo methods for evaluation of vaccine quality and immunogenicity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The RNActive® platform designed by CureVac combines the use of co-delivered RNA and protamine (a polycationic peptide) complex as adjuvant, which has been shown to effectively trigger innate immune responses and enhance vaccine immunogenicity.
“A vaccine platform (RNActive®) was designed by CureVac186 combining the use of co-delivered RNA and protamine (a polycationic peptide) complex as adjuvant, which has been shown to effectively trigger innate immune responses and enhance vaccine immunogenicity.186–189”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [186]
The favorable safety profile of the CVnCoV vaccine candidate was confirmed at up to a 12 μg dose.
“The favorable safety profile of the CVnCoV vaccine candidate126,127 using the RNActive mRNA vaccine platform developed by CureVac128 was confirmed at up to a 12 μg dose,129”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [128]
The citation lists haven’t been fetched yet
References 15 · Cited by 57
- Authors
- Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., & Heidenreich, R.
- Affiliations
- CureVac (Germany) (DE)
- Corresponding author
- Heidenreich, Regina
- Venue
- Methods in Molecular Biology
- Publisher
- Springer New York
- Published
- 2016-12-17
- Volume
- 1499
- Pages
- 89-107
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W2564437942
- Cited by
- 57
- References
- 15
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 8 · 2021: 12 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 2
- FWCI
- 4.10
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Methods in molecular biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA vaccines, protamine, mRNA stabilization, immunogenicity, mRNA synthesis, mRNA purification
- MeSH terms
- Immunogenicity, Vaccine, Animals, RNA, Messenger, Vaccines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
